Summary
36 pharmacokinetic studies of amikacin were performed to evaluate the bronchial diffusion of amikacin in 9 children with cystic fibrosis, 3 to 15 years old. Amikacin was administered i.v. according to a variable dosage regimen. Four children without cystic fibrosis were enrolled as controls. The mean half life was 1.1, the volume of distribution averaged 0.26 l/kg, and the mean plasma clearance was 131 ml/min/1.73 m2, which no differed from that of the controls. The mean peak plasma concentration was always above the MIC but its level depended on the unit dose: 18.5 mg/l, 25,95 mg/l and 31,46 mg/l for doses of 5, 7.5 and 12.5 mg/kg, respectively. Between consecutive amikacin infusions, the plasma level was above the MIC for 21% and 46% of the time after the 5 and 7.5 mg/kg doses. The maximum concentration in sputum between H1 and H2 was always below the MIC, except after 15 mg/kg. The ratio AUC sputum/AUC plasma was between 0.028 and 0.61, and it increased from the beginning to the end of the course of treatment. No side effects were observed on hearing, or vestibular and renal function. The results are used to suggest more appropriate dosing regimens.
Similar content being viewed by others
References
Beaudry Ph, Marks MI, Mc Dougall D, Desmond K, Rangel R (1980) Is anti-pseudomonas therapy warranted in acute respiratory exacerbations in children with cystic fibrosis. J Pediatr 97: 144–147
Boxerbaum B (1982) The art and science of the use of antibiotics in cystic fibrosis. Pediatr Infect Dis 1: 381–383
Eller JJ, Klinger JD, Hilton C, Bass JA (1977) Amikacin treatment of pseudomonas pneumonia in cystic fibrosis patients with advanced pulmonary involvement. Am J Med 62 [Suppl]: 179–185
Finkelstein E, Hall K (1979) Aminoglucoside clearance in patients with cystic fibrosis. J Pediatr 94: 163–164
Huang NN, Laraya-Cuasay LR, Yasmin N, Keith HH, Borden M, Cundy KR (1977) Clinical experience with amikacin in patients with cystic fibrosis. Am J Med 62: 186–195
Hyatt AC, Chipps BE, Kumor KM, Mellits ED, Lietman PS, Rosenstein BJ (1981) A double blind controlled trial for antipseudomonas chemotherapy of acute respiratory exacerbations in patients with cystic fibrosis. J Pediatr 99: 307–314
Kearns GL, Hilman BC, Wilson JT (1982) Dosing implications of altered gentamicin disposition in patients with cystic fibrosis. J Pediatr 100: 312–318
Kelly HB, Menendez R, Fan L, Murphy S (1982) Pharmacokinetics of tobramycin in cystic fibrosis. J Pediatr 100: 318–321
Lau WK, Young LS, Osher AB, Dooley R (1977) Amikacin therapy of exacerbation of pseudomonas aeruginosa infections in patients with cystic fibrosis. Pediatrics 60: 372–377
Levy J, Smith AL, Koup JR, Warren JW, Ramsey B (1984) Disposition of tobramycin in patients with cystic fibrosis: a prospective controlled studies. J Pediatr 105: 117–124
Mc Donald N, Anas NG, Peterson RG, Schwartz RH, Brooks J, Powell KR (1980) Renal clearance of gentamicin in cystic fibrosis. J Pediatr 103: 985–990
Malmborg AS, Alfredsson H, Kusoffsky E, Strandvik B (1981) Azlocillin and gentamicin in respiratory tract infections with pseudomonas aeruginosa in patients with cystic fibrosis. Scand J Infect Dis (suppl.29): 64–69
Marchand S, Thompson R, Autret E, Grenier B (1986) Concentration bronchique d'amikacine et décroissance bactérienne au cours des cures intensives d'antibiotiques chez l'enfant atteint de mucoviscidose. Pediatr Pharmacol (in press)
Marks MI (1981) The pathogenesis and treatment of pulmonary infections in patients with cystic fibrosis. J Pediatr 98: 173–179
Martin AJ, Smalley CA, George RH, Healting DE, Anderson CM (1980) Gentamicin and tobramycin compared in the treatment of mucoid pseudomonas lung infections in cystic fibrosis. Arch Dis Child 55: 604–607
Moller NE, Hoby N (1981) Antibiotic treatment of chronic pseudomonas aeruginosa infection in cystic fibrosis patients. Scand J Infect Dis 24 [suppl]: 87–91
Mombelli G, Coppens L, Thys JP, Klastersky J (1979) Antipseudomonas activity in bronchial secretions of patients receiving amikacin or tobramycin as a continuous intravenous infusion. Curr Chemoth Infect Dis, 19th ICAAC, Boston 1979: 657–659.
Rowland M, Tozer T (1980) Clinical pharmacokinetics. Concepts and applications. Lea & Febiger, Philadelphia
Smith CR, Baughman KL, Edwards LQ, Rogers JF, Lietman PS (1977) Controlled comparaison of amikacin and gentamicin. N Engl J Med 7: 349
Vogelstein B, Kowarski AA, Lietman PS (1977) The pharmacokinetecs of amikacin in children. J Pediatr 91: 333
Wientzen R, Prestidge CB, Kramer RI, Mc Cracken GH, Nelson JD (1980) Acute pulmonary exacerbations in cystic fibrosis. Am J Dis Child 134: 1134–1138
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Autret, E., Marchand, S., Breteau, M. et al. Pharmacokinetics of amikacin in cystic fibrosis: A study of bronchial diffusion. Eur J Clin Pharmacol 31, 79–83 (1986). https://doi.org/10.1007/BF00870991
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00870991